- Home
- QTTB vs LSB Comparison
QTTB vs LSB Comparison
Compare QTTB & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- LSB
- Stock Information
- Founded
- QTTB 2015
- LSB 2002
- Country
- QTTB United States
- LSB China
- Employees
- QTTB N/A
- LSB N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- QTTB Health Care
- LSB
- Exchange
- QTTB Nasdaq
- LSB NYSE
- Market Cap
- QTTB 19.0M
- LSB 22.3M
- IPO Year
- QTTB N/A
- LSB N/A
- Fundamental
- Price
- QTTB $1.55
- LSB $0.94
- Analyst Decision
- QTTB Hold
- LSB
- Analyst Count
- QTTB 8
- LSB 0
- Target Price
- QTTB $24.00
- LSB N/A
- AVG Volume (30 Days)
- QTTB 97.2K
- LSB 21.6K
- Earning Date
- QTTB 08-07-2025
- LSB 07-07-2025
- Dividend Yield
- QTTB N/A
- LSB N/A
- EPS Growth
- QTTB N/A
- LSB N/A
- EPS
- QTTB N/A
- LSB N/A
- Revenue
- QTTB N/A
- LSB $79,415,311.00
- Revenue This Year
- QTTB N/A
- LSB $39.33
- Revenue Next Year
- QTTB N/A
- LSB $75.61
- P/E Ratio
- QTTB N/A
- LSB N/A
- Revenue Growth
- QTTB N/A
- LSB N/A
- 52 Week Low
- QTTB $1.38
- LSB $0.36
- 52 Week High
- QTTB $53.79
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- QTTB 40.47
- LSB 37.29
- Support Level
- QTTB $1.47
- LSB $0.91
- Resistance Level
- QTTB $1.65
- LSB $1.03
- Average True Range (ATR)
- QTTB 0.12
- LSB 0.06
- MACD
- QTTB -0.02
- LSB 0.01
- Stochastic Oscillator
- QTTB 15.69
- LSB 43.75
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.